Free Trial
NASDAQ:FTH

Sensei Biotherapeutics Q2 2025 Earnings Results & Report

Sensei Biotherapeutics logo
$11.58 -1.77 (-13.28%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sensei Biotherapeutics beat analyst earnings expectations in its Q2 2025 results, released August 5, 2025. The company reported EPS of -$3.91 versus the -$6.20 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Sensei Biotherapeutics EPS Results

Actual EPS
-$3.91
Consensus EPS
-$6.20
Beat/Miss
Beat by +$2.29
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sensei Biotherapeutics Q2 2025 Earnings FAQ

Sensei Biotherapeutics (NASDAQ:FTH) reported earnings of -$3.91 per share for Q2 2025, beating the consensus estimate of -$6.20. The report was announced on Tuesday, August 5, 2025.

Sensei Biotherapeutics Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Analyst Firms Have Faith In Faeth Therapeutics
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:FTH) is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells.

The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.

Based in the United States, Sensei has focused its work on oncology research and development. Its approach has included developing antibody-based medicines and other immunotherapies for potential use alone or alongside existing cancer treatments.

View Sensei Biotherapeutics Profile